RT Journal Article
SR Electronic
T1 The effect of primary health care on AIDS incidence and mortality: a cohort study of 3.4 million Brazilians
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.02.23296417
DO 10.1101/2023.10.02.23296417
A1 Pinto, Priscila FPS
A1 Macinko, James
A1 Silva, Andréa F
A1 Lua, Iracema
A1 Jesus, Gabriela
A1 Magno, Laio
A1 Santos, Carlos AS Teles
A1 Ichihara, Maria Yury
A1 Barreto, Mauricio L
A1 Moucheraud, Corrina
A1 Souza, Luis E
A1 Dourado, Inês
A1 Rasella, Davide
YR 2023
UL http://medrxiv.org/content/early/2023/10/03/2023.10.02.23296417.abstract
AB Background Primary Health Care (PHC) is essential for the health and wellbeing of people living with HIV/AIDS. This study evaluated the effects of one of the largest community-based PHC programs in the world, the Brazilian Family Health Strategy (FHS), on AIDS incidence and mortality.Methods A retrospective cohort study carried out in Brazil, from January 1 2007 to December 31 2015. We conducted a quasi-experimental effect evaluation using a cohort of 3,435,068 ≥13 years low-income individuals who were members of the 100 Million Brazilians Cohort, linked to AIDS diagnoses and deaths registries. We evaluated the effect of FHS on AIDS incidence and mortality and comparing outcomes between residents of municipalities with no FHS coverage with those in municipalities with full FHS coverage. We used multivariable Poisson regressions adjusted for all relevant municipal and individual-level demographic, socioeconomic, and contextual variables, and weighted with inverse probability of treatment weighting (IPTW). We also estimated FHS effect by sex and age, and performed a wide range of sensitivity and triangulation analyses.Findings FHS coverage was associated with lower AIDS incidence (rate ratio [RR]:0.76, 95%CI:0.68–0.84) and mortality (RR:0.68,95%CI:0.56–0.82). FHS effect was similar between men and women, but was larger in people aged ≥35 years old both for incidence (RR 0.62, 95%CI:0.53–0.72) and mortality (RR 0.56, 95%CI:0.43– 0.72).Conclusions AIDS should be an avoidable outcome for most people living with HIV today, and our study shows that FHS coverage could significantly reduce AIDS incidence and mortality among low-income populations in Brazil. Universal access to comprehensive healthcare through community-based PHC programs should be promoted to achieve the Sustainable Development Goals of ending AIDS by 2030.Funding Funded by the National Institute of Allergy and Infectious Diseases - NIAID/NIH, Grant Number: 1R01AI152938.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265253 Funding StatementFunding: Funded by the National Institute of Allergy and Infectious Diseases - National Institutes of Health (NIAID/NIH), Grant Number: 1R01AI152938 awarded to Davide Rasella. We acknowledge support from the grant CEX2018-000806-S funded by MCIN/AEI/ 10.13039/501100011033, and support from the Generalitat de Catalunya through the Centres de Recerca de Catalunya (CERCA Program). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the research ethics committee of the Federal University of Bahia, under number 41691315.0.0000.5030 (Report No:3.783.920). The ‘100 Million Brazilians Cohort’ is based on the linkage of administrative data and did not require an additional consent form.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data supporting the findings presented were obtained from the Centro de Integração de Dados e Conhecimentos para Sauúde (CIDACS). Importantly, restrictions apply to access to the data, which contains sensitive information, were licensed for exclusive use in the current study and, due to privacy regulations from the Brazilian Ethics Committee are not openly available. Upon reasonable request and with express permission from CIDACS (mail to cidacs.curadoria@fiocruz.br) and approval from an thical committee, controlled access to the data is possible. The dataset is registered under the following DOI handle: https://hdl.handle.net/20. 500.12196/CIDACS/65, which provides metadata and a register of all versions of the database https://hdl.handle.net/20.500.12196/CIDACS/65